Dermata Therapeutics, Inc. (DRMA)
NASDAQ: DRMA · Real-Time Price · USD
0.7040
-0.0040 (-0.56%)
Jun 5, 2025, 2:58 PM - Market open

Dermata Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Net Income
-11.46-12.29-7.79-9.61-7.9-3.24
Upgrade
Depreciation & Amortization
-----0
Upgrade
Other Amortization
----0.010.1
Upgrade
Stock-Based Compensation
0.110.660.520.931.91-
Upgrade
Other Operating Activities
------0.13
Upgrade
Change in Accounts Payable
0.04-0.110.37-0.020.41-0.23
Upgrade
Change in Other Net Operating Assets
0.920.580.49-0.14-0.12-0.52
Upgrade
Operating Cash Flow
-10.39-11.16-6.41-8.83-5.69-4.03
Upgrade
Short-Term Debt Issued
----1.562.97
Upgrade
Long-Term Debt Issued
-----0.13
Upgrade
Total Debt Issued
----1.563.11
Upgrade
Long-Term Debt Repaid
-----0.56-0.81
Upgrade
Net Debt Issued (Repaid)
----1.012.3
Upgrade
Issuance of Common Stock
15.436.897.614.2815.39-
Upgrade
Repurchase of Common Stock
-0-0-0---
Upgrade
Other Financing Activities
-0.05-----
Upgrade
Financing Cash Flow
15.386.897.614.2815.962.57
Upgrade
Net Cash Flow
4.99-4.281.2-4.5610.27-1.46
Upgrade
Cash Interest Paid
----00.06
Upgrade
Cash Income Tax Paid
000000
Upgrade
Levered Free Cash Flow
-5.13-6.65-3.64-5.59-2.49-2.76
Upgrade
Unlevered Free Cash Flow
-5.13-6.65-3.64-5.59-2.48-2.74
Upgrade
Change in Net Working Capital
-1.49-0.52-0.860.47-0.530.76
Upgrade
Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q